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A conserved N-glycan present within the V3 loop of gp120 modulates the sensitivity to neutralization by antibodies directed
to the V3 loop. A glycan-deficient mutant of HIVLAI , designated HIVA308 , displayed a 100-fold increase in sensitivity to neutralization
by anti-V3 MAb NEA-9205 compared to wild-type HIVLAI . This difference in sensitivity was not caused by an alteration of the
antibody binding site itself, as NEA-9205 had equal affinity for both wild-type and mutant monomeric gp120. In contrast, virion-
associated wild-type gp120 was immunoprecipitated less efficiently with NEA-9205 than virion-associated mutant gp120. This
difference was completely abrogated, if immunoprecipitation were carried out in the presence of detergent. Furthermore, treatment
of virion preparations with detergent exposed the C-terminal D7324 epitope, which is inaccessible on virion-associated gp120
but readily accessible on monomeric, soluble gp120. Finally, both wild-type and mutant monomeric, soluble gp120 were precipi-
tated equally efficiently by NEA-9205 in the absence of detergent. Thus, the NEA-9205 epitope was readily accessible on
monomeric gp120 regardless of the presence of the 306N-glycan, and inaccessibility of the NEA-9205 epitope imparted by the
306N-glycan was observed only on the intact envelope oligomer. q 1996 Academic Press, Inc.
The envelope glycoprotein (Env) of human immunode- bile and gp120 may dissociate spontaneously (McKeat-
ing et al., 1991). gp120 thus shedded into the medium isficiency virus type 1 (HIV-1) promotes binding of virus to
cells expressing the surface antigen CD4, and subse- monomeric (Earl et al., 1990; Malvoisin and Wild, 1994).
Studies of oligomeric viral envelope proteins suggestquent events involving Env lead to fusion between viral
and plasma membranes. In addition to these functions that antigenicity of the oligomer is distinct from the mono-
mer (Broder et al., 1994; Poumbourios et al., 1992; Yew-critical to the initiation of infection, Env is a target for
neutralizing antibodies generated in the host. The Env dell et al., 1988). Thus, antibodies can be categorized
by virtue of their relative affinity for the oligomeric andglycoprotein is synthesized as a single polypeptide pre-
cursor, gp160. During and after translation gp160 folds monomeric forms of envelope protein. Also continuous
epitopes such as the V3 loop of gp120 may be sensitivein the ER and acquires the ability to oligomerize before
export to the Golgi (Earl et al., 1991). In the Golgi the to quaternary structure (Broder et al., 1994).
Back et al. (1994) identified an N-linked oligosaccha-precursor is proteolytically cleaved to create two nonco-
valently associated subunits: gp120, which is the surface ride at position 301 within the V3 loop of the HXB2 and
HX10 strains of HIV-1 that influenced the sensitivity toprotein of HIV-1, and gp41, which is the transmembrane
protein of HIV-1. gp160 assembles posttranslationally neutralization by antibodies directed to the V3 loop. We
obtained similar results using molecular clones of theinto dimers and higher order oligomers, most probably
as dimers of dimers (Earl et al., 1990; Poumbourios et LAI strain of HIV-1 (Hansen et al., 1996) and showed
that if subjected to selection with neutralizing antibodiesal., 1995). In agreement with this, the Env protein isolated
from virions has been reported to exist as a tetrameric directed to the V3 loop, variants lacking the specific oli-
gosaccharide rapidly develop resistance to neutralizationform (Pinter et al., 1989; Schawaller et al., 1989). The
ectodomain of gp41 constitutes the assembly domain of through acquisition of the oligosaccharide (Schønning et
al., 1996). In this report we study in detail the mechanismthe Env oligomer and is largely responsible for oligomer
formation and stability (Earl et al., 1990; Poumborios et for the differential sensitivity to V3-directed neutralization
imparted by the oligosaccharide.al., 1995). In contrast the gp41–gp120 association is la-
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described by Durda et al. (1990) and designated 5023, culture supernatant was determined relative to an HIV-
Ag standard using the ELISA described above. Culturewas raised against a synthetic peptide representing
amino acids 313 to 327 in the V3 loop of gp120 of the supernatants were diluted appropriately to obtain optical
densities within the linear range of the standard curve.LAI strain of HIV-1. D7324 (Moore and Jarrett, 1988), an
affinity purified sheep polyclonal antibody raised against
ELISA affinity determinationa synthetic peptide representing the 15 carboxy-terminal
amino acids of gp120 of the BH10 strain of HIV-1, was
ELISA affinity determinations were carried out essen-
obtained from Aalto Bio Reagents Ltd. HIV-Ig is a pool
tially as previously described by Moore et al. (1989) and
of serum obtained from HIV-infected individuals.
Moore (1990). Briefly, 96-well NUNC Maxisorp microtiter
plates were coated overnight with D7324 in 100 mMCells and virus
NaHCO3 , pH 8.5. Wells were washed twice with Tris-
buffered saline (TBS) to remove unbound antibody. ThenFor HIV infection experiments the CD4/ lymphocyte
cell lines MT-2, MT-4 (Harada et al., 1985), and H9 (Po- wells were blocked by incubation with TBS containing
2% skimmed milk powder. Wells were washed with TBSpovic et al., 1984) were cultured in growth medium at 377
in 5% CO2 . Growth medium was RPMI1640 with glutamax before addition of Triton X-100 treated HIV-Ag containing
culture supernatants diluted in TBS containing 10% fetal(GIBCO) supplemented with 10% heat-inactivated fetal
calf serum, 100 IU/ml penicillin, 20 mg/ml gentamicin, calf serum, 1% Triton X-100, 1% skimmed milk powder.
Wells were washed to remove unbound gp120. Thenand 100 IU/ml streptomycin.
HIVA308 was generated as previously described by sub- MAb NEA-9205 or HIV-Ig appropriately diluted in TBS
containing 2% skimmed milk powder, 20% sheep serum,jecting pBRU-2 to site-directed mutagenesis using the
U.S.E. Mutagenesis kit (Pharmacia) (Hansen et al., 1996). 0.5% Tween 20 was added. Wells were washed again
to remove unbound antibody before addition of eitherpBRU-2 contains the entire genome of HIVLAI . The muta-
tion introduced in HIVA308 changed the threonine present alkaline phospatase (AP)-conjugated sheep anti-mouse-
Ig (Bio-Rad) or AP-conjugated sheep anti-human-Ig (Bio-at position 308 in HIVLAI to an alanine, thereby eliminating
the site for N-linked glycosylation, N-X-T, present in HIV- Rad). AP-conjugated antibody was removed by washing
with AMPAK wash buffer and bound AP activity was de-LAI . To obtain viral stocks plasmid DNA was transfected
into H9 cells using the DEAE–Dextran method exactly termined using the AMPAK ELISA amplification system
(DAKO) according to the instructions of the manufacturer.as previously described (Gram et al., 1994). Clarified su-
pernatants were harvested at the peak of antigen produc- Initially, a dilution series of HIV-Ag containing superna-
tants was detected with a constant amount of HIV-Ig totion, aliquotted, and stored at 0807 until use.
determine the amount of immunoreactivity present in the
Infectivity and neutralization assay individual antigen preparation. Then isoreactive amounts
of antigen were added to the wells and detected with a
The infectious titer was determined by endpoint titra-
dilution series of either MAb NEA-9205 or HIV-Ig to detect
tion in a microtiter assay. A fourfold dilution series of the
differences in affinity.
individual viral stock in a volume of 100 ml of growth
medium was incubated in eight replicates in microtiter Radioimmunoprecipitation
wells for 1 hr at room temperature before the addition of
40,000 MT4 cells in 100 ml of growth medium. Cells were A total of 6 1 106 MT-2 cells were infected with either
HIVLAI or HIVA308 and cultured overnight in 5 ml of growththen cultured for 4 days when supernatant was har-
vested. The amount of HIV-Ag present in the supernatant medium. Then cells were washed and resuspended in 6
ml growth medium containing 300 mCi 3H-labeled glucos-was determined using an in-house biotin–avidin potenti-
ated double antibody HIV-Ag ELISA as described pre- amine hydrocloride (Amersham) and cultured for 4 days
when the culture supernatant was harvested and clari-viously (Nielsen et al., 1987). Cultures displaying an opti-
cal density twofold above the mean of two uninfected fied by filtration (0.45 mm).
Before immunoprecipitation, virions were separatedcultures were considered positive for HIV infection. The
TCID50 was determined as the reciprocal value of the from soluble protein by centrifugation (15,000 g; 1 hr).
Initial experiments showed that more than 97% of thedilution at which 50% of the cultures were infected, using
the Reed–Muench method (Reed and Muench, 1938). infectivity present in the culture supernatant was recov-
ered in the pellet using these conditions. Virion-con-In the neutralization assay 50 TCID50 of either HIVLAI
or HIVA308 was preincubated in four replicates in microti- taining pellets were gently resuspended in PBS and di-
vided in two. One virion suspension was adjusted to ater wells with a dilution series of NEA-9205 or the lectin
Concanavalin A (Sigma) in a volume of 100 ml growth final concentration of 1% Triton X-100 for precipitation of
lysed virions; the other was adjusted to an identical vol-medium for 1 hr before addition of 40,000 MT4 cells in
100 ml of growth medium. Cells were then cultured as ume with PBS for precipitation of whole virions. When
indicated, precipitation was carried out on the virion-described for the infectivity assay. HIV-Ag present in the
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depleted supernatant as well. HIV-Ig, D7324, or NEA-
9205 was coupled to protein A–Sepharose (PAS; Phar-
macia) in the absence of detergent and the antigen prep-
arations described above were incubated with identical
volumes of PAS-conjugated antibody for 3 hr at RT. Then
the Sepharose was pelleted and washed twice in lysis
buffer (1% Triton X-100, 1 mM EDTA, 100 mM NaCl, 20
mM Tris–HCl, pH 8.0, 100 IU/ml aprotinin, and 0.1% albu-
min) and twice in 10 mM Tris–HCl, 10 mM NaCl. Samples
were then resuspended in 60 ml of sample buffer (2%
SDS, 250 mM DTT, 0.2% tetramethylethyldiamin, 0.01%
Pyronine Y, and 10% glycerol in 0.4 M Tris H2SO4 buffer,
pH 7.2), boiled for 3 min, and pelleted and the superna-
tant was subjected to SDS–polyacrylamide gel electro-
phoresis. After fixation, gels were incubated in amplifica-
tion liquid (Amplify, Amersham), dried, and placed on
Kodak XAR-5 film.
Films were analyzed by scanning densitometry using
QuantiscanR software (Microbial Systems Ltd.).
RESULTS
Molecular clones of HIVLAI lacking the
306N-glycan are
generally sensitive to neutralization by antibody directed
to the V3 loop (Back et al., 1994; Hansen et al., 1996).
We subjected HIVLAI , which possesses the
306N-glycan,
FIG. 1. Modulation of sensitivity to V3-directed neutralization by theand HIVA308 , which lacks the
306N-glycan, to neutralization
306N-glycan. HIVLAI (solid squares) and HIVA308 (open squares) showedwith NEA-9205, a MAb raised against the V3 loop of differential sensitivity to neutralization by NEA-9205 (A), but similar
HIVLAI , and Concanavalin A (Con A), a lectin able to neu- sensitivity to neutralization by Concanavalin A (B). In the figure the
tralize HIV. As seen in Fig. 1A HIVA308 displayed an ap- mean antigen produced in quadruplicate cultures is shown normalized
to the amount of antigen produced in mock-treated cultures. SEM isproximately 100-fold increase in sensitivity to V3-medi-
shown in error bars.ated neutralization (IC50  0.0043 mg/ml) compared to
HIVLAI (IC50  0.4 mg/ml). This difference in sensitivity
could not be attributed to differences in the preparation either HIV-Ig or NEA-9205. The results of a representative
experiment are shown in Fig. 2. No difference in affinityof viral stocks, since HIVLAI and HIVA308 were equally
sensitive to neutralization with Con A (IC50  0.36 mg/ml of either HIV-Ig or NEA-9205 was observed between HIV-
LAI and HIVA308 . The concentration of MAb yielding halfand IC50 0.24 mg/ml for HIVLAI and HIVA308 , respectively)
as seen in Fig. 1B. The concentrations of Con A employed maximal binding can be used as an approximation for
the affinity constant (kD) of the gp120–MAb interactionin the neutralization assay were nontoxic to the cells
as indicated by an MTT (diphenyl tetrazolium bromide) (Moore, 1990). Half maximal binding occurred at 0.78 nM
for HIVLAI and at 0.75 nM for HIVA308 in the experimentconversion assay (Hansen et al., 1989). Thus, HIVLAI and
HIVA308 displayed differential sensitivity to neutralization shown in Fig. 2. Thus, the epitope of NEA-9205 was
present in both HIVLAI and HIVA308 . Furthermore, the ob-with NEA-9205.
To analyze the mechanism underlying the differential served differential sensitivity to neutralization could not
be attributed to differences in binding affinity of NEA-sensitivity to neutralization, binding studies were made
using virus preparations treated with Triton X-100 9205 to immobilized gp120.
These findings prompted us to investigate if the differ-(Tx100). In this assay MAb was titrated against gp120
captured onto a solid phase with D7324, a sheep anti- ential sensitivity to neutralization of HIVLAI and HIVA308
was reflected by differential affinity of NEA-9205 to virion-body specific for the C terminus of gp120. Initially, the
amount of gp120 present in virus preparations of HIVLAI associated gp120. Accordingly, a dilution series of NEA-
9205 was coupled to protein A-conjugated Sepharoseand HIVA308 was titrated for their relative immunoreactiv-
ity to serum obtained from HIV-seropositive individuals and used to immunoprecipitate virions in the presence
and absence of Tx100. Furthermore, the antigen prepara-(HIV-Ig) to ensure that isoreactive amounts of wild-type
and mutant gp120 were captured to the solid phase. tions were precipitated with HIV-Ig under the same ex-
perimental conditions and the amount of gp120 precipi-Then amounts equally reactive with HIV-Ig were loaded
to the solid phase and detected with titrated amounts of tated by HIV-Ig was used to normalize for differences in
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against the conserved carboxy terminus of gp120, which
has been proposed to be engaged in the association of
gp120 with gp41 (Helseth et al., 1991; Moore et al., 1994).
HIVLAI virions were separated from soluble gp120 by cen-
trifugation and both resuspended virions and the virion-
depleted supernatant containing soluble gp120 were im-
munoprecipitated with D7324 in the presence and ab-
sence of 1% Tx100. As seen in Fig. 4A only trace amounts
of gp120 detectable only after prolonged exposure were
precipitated by D7324 from a virion suspension in the
absence of Tx100. In contrast, D7324 readily precipitated
gp120 from the virion-depleted supernatant in the ab-
sence of detergent (Fig. 4B). These findings are compati-
ble with the notion that the C terminus of gp120 is readily
accessible on soluble gp120, but inaccessible when
gp120 is associated with gp41. We attribute the trace
amount of gp120 precipitated by D7324 from a virion
FIG. 2. Binding of NEA-9205 to immobilized HIVLAI and HIVA308 gp120.
HIVLAI gp120 (solid squares) and HIVA308 gp120 (open squares) were
captured to a solid phase by D7324 and subsequently detected with
either NEA-9205 (A) or HIV-Ig (B). The background signal, i.e., the OD490
obtained without gp120 captured to the solid phase is shown (x). The
standard deviation of duplicate determinations is shown in error bars;
if not indicated the standard deviation is within the symbol. In this
assay NEA-9205 bound HIVLAI and HIVA308 gp120 with equal affinity (A)
when amounts isoreactive with HIV-Ig (B) were loaded to the solid
phase.
the amount of antigen and specific label present in the
preparations of HIVLAI and HIVA308 . As seen in Fig. 3A
significantly less HIVLAI gp120 than HIVA308 gp120 was
precipitated from virion suspensions in the absence of
Tx100. It may be noted that virion-associated HIVA308
gp120 bound approximately the same amount of antibody
as virion-associated HIVLAI gp120 in the presence of 125
times more antibody (Fig. 3A). This difference suggested
a difference in affinity of NEA-9205 to HIVLAI virion-associ-
FIG. 3. Immunoprecipitation of virion suspensions by NEA-9205.ated gp120 compared to HIVA308 virion-associated gp120
gp120 present in virion suspensions of HIVLAI (solid squares) andof at least 100-fold, explaining the difference in neutral-
HIVA308 (open squares) were precipitated with PAS-conjugated NEA-ization sensitivity. In contrast, as seen in Fig. 3B, HIVLAI 9205 and HIV-Ig in the absence of Tx100 (A) or in the presence of 1%
gp120 and HIVA308 gp120 were precipitated equally effi- Tx100 (B). In the figure the resulting gp120 bands are shown as an
ciently, if precipitation was carried out in the presence insert in addition to a densitometric analysis. The bands inserted result
from precipitation with HIV-Ig (marked control) and 0.1, 0.6, 2.8, and 14of Tx100. Thus, the presence of Tx100 eliminated the
mg/ml NEA-9205, respectively (left to right). For analysis, values ob-difference in affinity in agreement with the results ob-
tained with NEA-9205 were expressed relative to values obtained withtained above using immobilized gp120.
HIV-Ig. In the absence of Tx100 considerably less HIVLAI gp120 thanTo determine the effect of Tx100 on virion preparations, HIVA308 gp120 was precipitated by NEA-9205 (A). This difference be-
we investigated the accessibility of the epitope of D7324 tween HIVLAI and HIVA308 was completely abrogated in the presence of
Tx100 (B).in the absence and presence of Tx100. D7324 is directed
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FIG. 4. Accessibility of the D7324 epitope on HIVLAI gp120. HIVLAI gp120 was precipitated from either virion suspensions (A) or virion-depleted
supernatants (B) with D7324-conjugated PAS (D7324), HIV-Ig-conjugated PAS (HIV-Ig), or unconjugated PAS (PAS) in the absence or presence of
1% Tx100 as indicated in the figure. The migration of a molecular weight standard is indicated with bars. The molecular weights of the individual
bands in the standard are 200, 100, 69, and 46 kDa. Only trace amounts of gp120 were precipitated by D7324 from virion suspensions in the
absence of Tx100 and the presence of 1% Tx100 exposed the D7324 epitope (A). In contrast, the D7324 epitope was readily accessible on gp120
present in the virion-depleted supernatant whether Tx100 was present or not (B).
suspension to imperfect separation of soluble gp120 DISCUSSION
from virions and to gp120 shedded from virions during
Primary isolates of HIV are resistant to neutralizationimmunoprecipitation (McKeating et al., 1991). If Tx100
with soluble CD4, while laboratory-adapted isolates arewas present during precipitation, D7324 readily precipi-
sensitive (Daar et al., 1990). The difference in sensitivitytated gp120 from a thus treated virion suspension. Also,
cannot be attributed to differences in affinity of mono-precipitation of gp120 with HIV-Ig from virion suspen-
meric gp120 to CD4 (Turner et al., 1992; Ashkenazi et al.,sions was influenced by the presence of Tx100 but to
1991). In general, neutralization of primary isolates isa lesser degree than precipitation with D7324. These
not predicted by affinity studies using monomeric gp120,findings indicated that the presence of Tx100 caused the
whereas neutralization of laboratory-adapted isolates todissociation of gp120 from gp41. Conversely, the pres-
some extent is (Moore et al., 1995). Bou-Habib et al.ence of Tx100 did not affect the precipitation of gp120
(1994) reported the cryptic nature of the V3 loop in awith either D7324 or HIV-Ig from virion-depleted superna-
macrophage-tropic isolate. The cryptic V3 loop of thetants. This suggested that the presence of Tx100 did not
macrophage-tropic isolate used in this study becamealter the conformation of gp120 significantly.
The experiment above strongly suggested that Tx100
caused gp120 to dissociate from gp41. The effect of
Tx100 on the accessibility of the NEA-9205 epitope could
then formally be attributed to either the disruption of the
Env oligomer or a detergent effect on solubilized gp120.
To evaluate the latter possibility two experiments were
performed. In the first experiment HIVLAI and HIVA308
gp120 from virion-depleted supernatants were precipi-
tated with NEA-9205 in the absence of detergent. As
seen in Fig. 5, HIVLAI and HIVA308 gp120 were precipitated
equally efficiently. In the second experiment HIVLAI and
HIVA308 gp120 from virion-depleted supernatants were
precipitated with NEA-9205 in the presence of graded
concentrations of Tx100 (Fig. 6). The presence of Tx100
FIG. 5. Immunoprecipitation of virion-depleted supernatants by NEA-did not affect the efficiency of precipitation. Thus, the
9205. Virion-depleted supernatants from cultures of HIVLAI (solid
presence of Tx100 did not alter the accessibility of the squares) and HIVA308 (open squares) were precipitated in the absence
NEA-9205 epitope when gp120 was already solubilized. of Tx100. In the figure the resulting gp120 bands are shown as an
insert in addition to a densitometric analysis. The bands inserted resultWe therefore conclude that inaccessibility of the NEA-
from precipitation with HIV-Ig (marked control) and 0.1, 0.5, 2.6, and 139205 imparted by the 306N-glycan depends on quaternary
mg/ml NEA-9205, respectively (left to right). For analysis, values ob-
structure of the envelope oligomer and that the presence tained with NEA-9205 were expressed relative to values obtained with
of Tx100 exposes the NEA-9205 epitope by disrupting HIV-Ig. NEA-9205 bound HIVLAI and HIVA308 gp120 present in virion-
depleted supernatants equally efficiently.the quaternary structure of the envelope oligomer.
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That the V3 loop might be important as a neutralization
epitope was initially suggested by immunization experi-
ments using V3 peptides and recombinant gp120. In con-
trast, the significance of V3-directed antibodies in natural
infection is less clear. Immunization with preparations of
oligomeric Env generates only few antibodies directed
against the V3 loop (Earl et al., 1994). This finding is in
agreement with the notion that the V3 loop is poorly
exposed in the envelope oligomer. Furthermore, the ma-
jority of epitopes present on gp120 are more reactive
on monomeric than on oligomeric envelope glycoprotein
(Broder et al., 1994). Thus, it may be possible that immuni-
zation strategies employing recombinant, monomeric
FIG. 6. Effect of Tx100 on immunoprecipitation of virion-depleted
gp120 may induce predominantly nonprotective immunitysupernatants by NEA-9205. Virion-depleted supernatants from cultures
directed against epitopes that are inaccessible on oligo-of HIVLAI (solid squares) and HIVA308 (open squares) were precipitated
in the presence of graded concentrations of Tx100. The resulting gp120 meric, virion-associated envelope glycoprotein. A more
bands are shown as an insert in addition to a densitometric analysis. thorough understanding of the exposure of potential neu-
The bands inserted result from precipitation by NEA-9205 in the pres- tralization epitopes in the envelope oligomer and the
ence of Tx100 in the following concentrations: 0, 0.016, 0.063, 0.25, and
mechanisms that modulate the differential accessibility1% (left to right). For analysis, values obtained in the presence of Tx100
to epitopes in the Env monomer and oligomer is a prereq-were expressed relative to values obtained in the absence of Tx100.
The presence of Tx100 in concentrations up to 1% did not influence uisite for the rational design of a protective subunit vac-
the efficiency of precipitation of either HIVLAI or HIVA308 gp120 present cine. The demonstration of oligosaccharide-mediated
in virion-depleted supernatants. shielding as a mechanism that can confer a low accessi-
bility to a major neutralization epitope in the Env oligomer
may contribute to this understanding.exposed during prolonged passage and adaptation to
established T cell lines. In the study reported here, we
demonstrate that resistance to V3-directed neutralization ACKNOWLEDGMENTS
correlates with poor binding of the neutralizing MAb to
The pBRU2 plasmid was donated by Dr. Emerman through the AIDSthe Env oligomer and that binding studies using mono-
reagent project of the British Medical Research Council. This work wasmeric gp120 cannot predict neutralization. We are at
supported by the Danish Medical Research Council, the John & Birthe
present unable to discern whether the low binding con- Meyer Foundation, the Swedish Medical Research Council (Grants
figuration of the Env oligomer depends on gp41–gp120 9083 and 10437), the National Swedish Board for Technical Develop-
ment, and the Medical Faculty of the University of Go¨teborg.association, gp120–gp120 association, or both, but
whatever might prove to be the case, we show that the
low binding of neutralizing antibody to the envelope REFERENCES
oligomer depends critically on the presence of the 306N-
Ashkenazi, A., Smith, D. H., Marsters, S. A., Riddle, L., Gregory, T. J.,glycan. Furthermore, in the present study intact quater-
Ho, D. D., and Capon, D. J. (1991). Resistance of primary isolates ofnary structure is a prerequisite for the oligosaccharide
human immunodeficiency virus type 1 to soluble CD4 is independent
to effect a conformation where the epitope of the neu- of CD4–rgp120 binding affinity. Proc. Natl. Acad. Sci. USA 88, 7056–
tralizing MAb is poorly accessible. 7060.
Back, N. K. T., Smit, L., De Jong, J-J., Keulen, W., Schutten, M., Goudsmit,Using a prototypic T cell line adapted HIV isolate, Sat-
J., and Tersmitte, M. (1994). An N-glycan within the human immunode-tentau and Moore (1995) demonstrated that numerous
ficiency type 1 gp120 V3 loop affects virus neutralization. Virologyneutralizing MAbs except those reactive with V3 reacted
199, 431–438.
weaker with envelope oligomer than with monomeric Bou-Habib, D. C., Roderiquez, G., Oravecz, T., Berman, P. W., Lusso,
gp120. The accessibility of V3 on oligomeric Env ob- P., and Norcross, M. A. (1994). Cryptic nature of envelope V3 region
epitopes protects primary monocytotropic human immunodeficiencyserved in that study may be a characteristic of the spe-
virus type 1 from antibody neutralization. J. Virol. 68, 6006–6013.cific isolate employed rather than a general phenome-
Broder, C. C., Earl, P. L., Long, D., Abedon, S. T., Moss, B., and Doms,non. Thus, it has recently been reported that the envelope
R. W. (1994). Antigenic implications of human immunodeficiency virus
oligomer of macrophage-tropic isolates was inaccessi- type 1 envelope quaternary structure: Oligomer-specific and -sensi-
ble to V3 antibodies in contrast to the envelope oligomer tive monoclonal antibodies. Proc. Natl. Acad. Sci. USA 91, 11699–
11703.of T cell line adapted isolates (Sullivan et al., 1995; Sta-
Daar, E. S., Li, X. L., Moudgil, T., and Ho, D. D. (1990). High concentra-matatos and Cheng-Mayer, 1995). The BRU isolate of
tions of recombinant soluble CD4 are required to neutralize primaryHIVLAI employed in the present study, although adapted human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci.
to growth in T cell lines, resembles macrophage-tropic USA 87, 6574–6578.
isolates in the sense that the V3 loop is poorly accessible Durda, P. J., Bacheler, L., Clapham, P., Jenoski, A. M., Leece, B., Mat-
thews, T. J., McKnight, A., Pomerantz, R., Rayner, M., and Weinhold,in the envelope oligomer.
AID VY 7809 / 6a13$$$201 02-29-96 18:30:19 vira AP: Virology
140 SCHØNNING ET AL.
K. J. (1990). HIV-1 neutralizing monoclonal antibodies induced by a Robinson, J., Barbas III, C. F., Burton, D. R., and Ho, D. D. (1995).
Primary isolates of human immunodeficiency virus type 1 are rela-synthetic peptide. AIDS Res. Hum. Retroviruses 6, 1115–1123.
Earl, P. L., Doms, R. W., and Moss, B. (1990). Oligomeric structure of tively resistant to neutralization by monoclonal antibodies to gp120,
and their neutralization is not predicted by studies with monomericthe human immunodeficiency virus type 1 envelope glycoprotein.
Proc. Natl. Acad. Sci. USA 87, 648–652. gp120. J. Virol. 69, 101–109.
Nielsen, C. M., Bygbjerg, I. C., and Vestergaard, B. F. (1987). DetectionEarl, P. L., Moss, B., and Doms, R. W. (1991). Folding, interaction with
GRP78-BiP, assembly and transport of human immunodeficiency vi- of HIV antigens in eluates of whole blood collected on filter paper.
Lancet i, 566–567.rus type 1 envelope protein. J. Virol. 65, 2047–2055.
Earl, P. L., Broder, C. C., Long, D., Lee, S. A., Peterson, J., Chakrabarti, Pinter, A., Honnen, W. J., Tilley, S. A., Bona, C., Zaghouani, H., Gorny,
M. K., and Zolla-Pazner, S. (1989). Oligomeric structure of gp41, theS., Doms, R. W., and Moss, B. (1994). Native oligomeric human im-
mnodeficiency virus type 1 envelope glycoprotein elicits diverse transmembrane protein of human immunodeficiency virus type 1. J.
Virol. 63, 2674–2679.monoclonal antibody reactivities. J. Virol. 68, 3015–3026.
Gram, G. J., Hemming, A., Bolmstedt, A., Jansson, B., Olofsson, S., A˚ker- Popovic, M., Sarnagadharan, M. G., Read, E, and Gallo, R. C. (1984).
Detection isolation and continuos production of cytopathic retrovi-blom, L., Nielsen, J. O., and Hansen, J-E. S. (1994). Identification of
an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutral- ruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224,
497–500.ization by anti-V3 antibodies and soluble CD4. Arch. Virol. 139, 253–
261. Poumbourios, P., McPhee, A., and Kemp, B. E. (1992). Antibody epitopes
sensitive to the state of human immunodeficiency virus type 1 gp41Hansen, J-E. S., Jansson, B., Gram, G. J., Clausen, H., Nielsen, J. O., and
Olofsson, S. (1996). Sensitivity of HIV-1 to neutralization by antibodies oligomerization map to a putative I-helical region. AIDS Res. Hum.
Retroviruses 8, 2055–2062.against O-linked carbohydrate epitopes despite deletion of O-glyco-
sylation signals in the V3 loop. Arch. Virol. 141, 291–300. Poumbourios, P., El Ahmar, W., McPhee, D. A., and Kemp, B. E. (1995).
Determinants of human immunodeficiency virus type 1 envelope gly-Hansen, M. B., Nielsen, S. E., and Berg, K. (1989). Re-examination and
further development of a precise and rapid dye method for measuring coprotein oligomeric structure. J. Virol. 69, 1209–1218.
Reed, L. J., and Muench, H. (1938). A simple method for estimating 50%cell growth/cell kill. J. Immunol. Methods 119, 203–210.
Harada, S., Koyanagi, Y., and Yamamato, N. (1985). Infection of HTLV- endpoint. Am. J. Hyg. 27, 493–497.
Sattentau, Q. J., and Moore, J. P. (1995). Human immunodeficiency virusIII/LAV in HTLV-I-carrying MT-2 and MT-4 cells and application in a
plaque assay. Science 229, 563–566. type 1 neutralization is determined by epitope exposure on the gp120
oligomer. J. Exp. Med. 182, 185–196.Helseth, E., Olshevsky, U., Furman, C., and Sodroski, J. (1991). Human
immunodeficiency virus type 1 envelope glycoprotein regions im- Schawaller, M., Smith, G. E., Skehel, J. J., and Wiley, D. C. (1989). Studies
with crosslinking reagents on the oligomeric structure of the envportant for association with the gp41 transmembrane glycoprotein.
J. Virol. 65, 2119–2123. glycoprotein of HIV. Virology 172, 367–369.
Schønning, K., Jansson, B., Olofsson, S., and Hansen, J-E. S. (1996).Malvoisin, E., and Wild, F. (1994). Analysis of the human immunodefi-
ciency virus type 1 envelope protein interaction with the host CD4 Rapid selection of an N-linked oligosaccharide by monoclonal anti-
bodies against the V3-loop of human immunodeficiency virus type 1host cell receptor. J. Gen. Virol. 75, 839–847.
McKeating, J. A., McKnight, A., and Moore, J. P. (1991). Differential loss (HIV-1). J. Gen. Virol. 77, 753–758.
Stamatatos, L., and Cheng-Mayer, C. (1995). Structural modulations ofof envelope glycoprotein gp120 from virions of human immunodefi-
ciency virus type 1 isolates: Effects on infectivity and neutralization. the envelope gp120 glycoprotein of human immuodeficiency virus
type 1 upon oligomerization and differential V3 loop epitope exposureJ. Virol. 65, 852–860.
Moore, J. P., and Jarrett, R. F. (1988). Sensitive ELISA for the gp120 and of isolates displaying distinct tropism upon virion-soluble receptor
binding. J. Virol. 69, 6191–6198.gp160 surface glycoprotein of HIV-1. AIDS Res. Hum. Retroviruses
4, 369–379. Sullivan, N., Sun, Y., Hofmann, W., and Sodroski, J. (1995). Replicative
function and neutralization sensitivity of envelope glycoproteins fromMoore, J. P., Wallace, L. A., Follett, E. A. C., and McKeating, J. A. (1989).
An enzyme-linked immunosorbent assay for antibodies to envelope primary and T-cell line-passaged human immunodeficiency type 1
isolates. J. Virol. 69, 4413–4422.glycoproteins of divergent strains of HIV-1. AIDS 3, 155–163.
Moore, J. P. (1990). Simple methods for monitoring HIV-1 and HIV-2 Turner, S., Tizard, R., DeMarinis, J., Pepinsky, R. B., Zullo, J., Schooley,
R., and Fisher, R. (1992). Resistance of primary isolates of humangp120 binding to soluble CD4 by enzyme-linked immunosorbent
assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. immunodeficiency virus type 1 to neutralization by soluble CD4 is
not due to lower affinity with the viral envelope glycoprotein gp120.AIDS 4, 297–305.
Moore, J. P., Sattentau, Q. J., Wyatt, R., and Sodroski, J. (1994). Probing Proc. Natl. Acad. Sci. USA 89, 1335–1339.
Yewdell, J. W. A., Yellen, A., and Bachi, T. (1988). Monoclonal antibodiesthe structure of the human immunodeficiency virus surface glycopro-
tein with a panel of monoclonal antibodies. J. Virol. 68, 469–484. localize events in the folding, assembly and intracellular transport
of the influenza virus hemagglutinin glycoprotein. Cell 52, 843–852.Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R.,
AID VY 7809 / 6a13$$$201 02-29-96 18:30:19 vira AP: Virology
